A5022130020- Treatment of Major Depression
- Bipolar Disorder and Treatment
- Mental Health Research Topics
- Schizophrenia research and treatment
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Functional Brain Connectivity Studies
- Electroconvulsive Therapy Studies
- Pharmaceutical studies and practices
- Neurological disorders and treatments
- Tryptophan and brain disorders
- Vagus Nerve Stimulation Research
- Attention Deficit Hyperactivity Disorder
- Neurotransmitter Receptor Influence on Behavior
- Diet and metabolism studies
- Child and Adolescent Psychosocial and Emotional Development
- Pharmaceutical Practices and Patient Outcomes
- Neuroscience and Neuropharmacology Research
- Transcranial Magnetic Stimulation Studies
- Cardiac electrophysiology and arrhythmias
- Pharmacogenetics and Drug Metabolism
- Stress Responses and Cortisol
- Pharmacological Effects and Toxicity Studies
- Sleep and related disorders
- Epilepsy research and treatment
- Pharmaceutical Economics and Policy
University of Pittsburgh
2011-2024
Yale New Haven Hospital
2024
Michael E. DeBakey VA Medical Center
2022
University of Pittsburgh Medical Center
2008-2018
Harvard University
2010
Pittsburg State University
2009-2010
Western Pennsylvania Hospital
2008
Salisbury University
1964
Selective serotonin reuptake inhibitors (SSRIs) are widely used to treat depression, but the rates, timing, and baseline predictors of remission in "real world" patients not established. The authors' primary objectives this study were evaluate effectiveness citalopram, an SSRI, using measurement-based care actual practice, identify symptom outpatients with major depressive disorder.This clinical included disorder who treated 23 psychiatric 18 settings. received flexible doses citalopram...
About half of outpatients with major depressive disorder also have clinically meaningful levels anxiety. The authors conducted a secondary data analysis to compare antidepressant treatment outcomes for patients anxious and nonanxious depression in Levels 1 2 the STAR*D study.A total 2,876 adult disorder, enrolled from 18 primary 23 psychiatric care sites, received citalopram Level STAR*D. In 2, 1,292 who did not remit or tolerate were randomly assigned either switch sustained-release...
Approximately all clinically useful antipsychotic drugs have known activity as dopamine receptor antagonists, but many of these also are inverse agonists at the serotonin-2A (5HT2A) receptor. Pimavanserin is an agonist 5HT2A receptor, with a lower binding affinity serotonin-2C and sigma 1 no significant to or other receptors. Because its unique pharmacology, pimavanserin was approved for treatment psychosis associated Parkinson's disease, it has low risk exacerbating motor symptoms compared...
To identify baseline sociodemographic and clinical factors associated with a current chronic major depressive episode (MDE).Outpatients disorder enrolled in 41 US primary or psychiatric care sites were divided into two groups based on self-report of length (<24 > =24 months). Logistic regression models used to chronicity episode.About 21.2% 1380 subjects current, MDEs. Older age, less education, lower income, no private insurance, unemployment, greater general medical illness burden,...
Intravenous ketamine, which displays rapid antidepressant properties, is posited to reverse depression by rapidly enhancing neuroplasticity. The authors tested whether an automated, computer-based approach could efficiently leverage enhanced neuroplasticity extend the durability of clinical response.A total 154 adults (ages 18-60) with treatment-resistant unipolar were randomized in a double-blind, parallel-arm design receive active/active treatment combination (ketamine plus active...
Intravenous ketamine is posited to rapidly reverse depression by enhancing neuroplasticity. In human patients, we quantified gray matter microstructural changes on a rapid (24-h) timescale within key regions where neuroplasticity enhancements post-ketamine have been implicated in animal models. this study, 98 unipolar depressed adults who failed at least one antidepressant medication were randomized 2:1 single infusion of intravenous (0.5 mg/kg) or vehicle (saline) and completed diffusion...
<h3>Context</h3> Although various strategies are available to manage nonresponders an initial treatment for depression, no controlled trials address the utility of switching from antidepressant medication psychotherapy or vice versa. <h3>Objective</h3> To compare responses chronically depressed 12 weeks with either nefazodone cognitive behavioral analysis system (CBASP) who were crossed over alternate (nefazodone, n = 79; CBASP, 61). <h3>Design</h3> Crossover trial. <h3>Setting</h3> Twelve...
Although various strategies have been proposed to treat antidepressant nonresponders, little controlled research has published that examines prospectively the use of switching an alternate antidepressant.This was a multisite study in which outpatients with chronic major depression (with or without concurrent dysthymia), who failed respond 12 weeks double-blind treatment either sertraline hydrochloride (n = 117) imipramine 51), were crossed over switched additional medication. Outcome...
Objective: Premature attrition from treatment may lead to worse outcomes and compromise the integrity of clinical trials in major depressive disorder. The purpose this study was identify pretreatment predictors during acute with citalopram a large, "real world" trial. Method: A total 4,041 adult outpatients nonpsychotic disorder were enrolled for up 14 weeks. Attrition defined as "immediate" (patients who attended baseline visit only) or "later" at least one postbaseline but dropped out...